The Asia-Pacific (APAC) region is increasingly recognized as a strategic hub for global clinical research. With its vast and diverse patient populations, a blend of cost structures, and expanding government support, APAC offers unique advantages for sponsors seeking speed, scale, and efficiency. For clinical operations teams, success in APAC depends on understanding how to align trial needs with country-specific strengths while navigating local regulatory and cultural nuances.Â
APACâs Role in Todayâs Clinical Trial StrategyÂ
The APAC region is home to a large and diverse population, including India and China, 2 of the worldâs most populous countries, each projected to exceed 1.4 billion people in 2025. The region offers a mix of high- and low-cost countries, with several governments providing incentives that enhance cost-effectiveness in clinical trial execution.Â
Healthcare infrastructure, site capabilities, and experienced staff in countries such as Australia, Hong Kong, New Zealand, South Korea, and Singapore contribute to shorter startup timelines. In addition, countries like China, Malaysia, and South Korea have demonstrated strong recruitment performance, often enrolling the first patient or becoming top recruiters regionally and globally.Â
Government support and increased R&D investment continue to grow across APAC, helping reduce operational costs. There is also a noticeable shift from late phase to early phase capabilities, particularly in China and Malaysia, where investment in phase I facilities is expanding. Countries such as China, India, and Japan remain key contributors to high-volume late phase trials, especially in oncology, cardiovascular, renal, and metabolic indications.Â
Innovation and biotech activity have increased significantly in China, Japan, and South Korea, with digital clinical trial models and AI-driven trial design gaining traction over the past 5 years.Â
Selecting the Right Countries for Each Trial PhaseÂ
Early Phase TrialsÂ
Country selection for early phase trials depends on several factors, including startup and recruitment timelines, patient prevalence, trial design (e.g., first-in-human or healthy volunteer studies), and regulatory and marketing strategies.Â
Australia and New Zealand are preferred destinations for early phase trials due to their streamlined regulatory frameworks. In Australia, most trials can be submitted under the Clinical Trial Notification (CTN) scheme, which simplifies the process. For high-risk investigational products, such as biologics involving human or animal cells, the Clinical Trial Approval (CTA) scheme is used. Both countries offer well-established phase I units, often in private settings, which support rapid startup and high-quality execution.Â
South Korea also presents a highly efficient environment for early phase trials, supported by a streamlined regulatory process that allows for rapid IND and IRB approvals. The country has over 170 certified trial sites and is known for generating high-quality data aligned with global standards. A centralized healthcare system and strong public health literacy contribute to efficient patient recruitment and retention. Government investment further enhances its appeal.Â
China is increasingly active in early phase trials, particularly among local biotech and pharmaceutical companies. The country offers advantages in cost, recruitment speed, and alignment with local marketing strategies. Additional countries such as Japan, Singapore, Taiwan, and Malaysia are also expanding their early phase capabilities.Â
Late Phase TrialsÂ
Japan is a strategic location for late phase trials due to its large and aging population, which is ideal for studies in oncology, cardiovascular, and neurodegenerative diseases. The Pharmaceuticals and Medical Devices Agency (PMDA) offers regulatory flexibility through early consultation and accelerated pathways. Japan is recognized for its rigorous compliance and high data quality, making its trial results highly credible and often essential for global regulatory submissions, particularly in multi-regional clinical trials (MRCTs). Regulatory requirements often mandate the inclusion of Japanese patient populations, making Japan a key destination for global sponsors.Â
Checklist for Effective Clinical Operations in APAC:Â
â
Understand regulatory timelines and approval pathways
â
Align trial design with local healthcare infrastructure
â
Plan for language and cultural differences in patient engagement
â
Collaborate with experienced regional partners
â
Monitor recruitment performance and adjust strategies as needed
â
Stay informed on government policies and R&D investmentsÂ
APAC offers real opportunities to improve trial timelines, reduce costs, and reach broader patient populations. With the right approach, clinical operations teams can deliver consistent results across a complex and fast-evolving region.Â
About the AuthorÂ
Siow Bee Seu is a seasoned clinical research professional with nearly 20 years of experience across the Asia-Pacific region. As Director of Clinical Operations for APAC at Indero (formerly Innovaderm), she leads trial operations across diverse markets. Her background includes over 15 years at George Clinical in roles such as Head of Project Operations for East Asia. With deep expertise in project management, regulatory strategy, and team leadership, Siow has a strong track record of driving successful research initiatives throughout APAC.Â
